Related references
Note: Only part of the references are listed.In vivo brain GPCR signaling elucidated by phosphoproteomics
Jeffrey J. Liu et al.
SCIENCE (2018)
Post-marketing surveillance study of the safety and efficacy of nalfurafine hydrochloride (Remitch® capsules 2.5 μg) in 3,762 hemodialysis patients with intractable pruritus
Hideki Kozono et al.
INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE (2018)
Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor
Selena S. Schattauer et al.
CELLULAR SIGNALLING (2017)
Phosphorylation Is a Central Mechanism for Circadian Control of Metabolism and Physiology
Maria S. Robles et al.
CELL METABOLISM (2017)
Phosphoproteomics in the Age of Rapid and Deep Proteome Profiling
Nicholas M. Riley et al.
ANALYTICAL CHEMISTRY (2016)
Determination of sites of U50,488H-promoted phosphorylation of the mouse κ opioid receptor (KOPR): disconnect between KOPR phosphorylation and internalization
Chongguang Chen et al.
BIOCHEMICAL JOURNAL (2016)
Biased agonism: An emerging paradigm in GPCR drug discovery
Zoran Rankovic et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation
M M Harraz et al.
MOLECULAR PSYCHIATRY (2016)
Mass-spectrometric exploration of proteome structure and function
Ruedi Aebersold et al.
NATURE (2016)
The Perseus computational platform for comprehensive analysis of (prote)omics data
Stefka Tyanova et al.
NATURE METHODS (2016)
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria
Tarsis F. Brust et al.
SCIENCE SIGNALING (2016)
Glucose-regulated and drug-perturbed phosphoproteome reveals molecular mechanisms controlling insulin secretion
Francesca Sacco et al.
NATURE COMMUNICATIONS (2016)
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria
Tarsis F. Brust et al.
SCIENCE SIGNALING (2016)
Kappa Opioid Receptor-Induced Aversion Requires p38 MAPK Activation in VTA Dopamine Neurons
Jonathan M. Ehrich et al.
JOURNAL OF NEUROSCIENCE (2015)
High-throughput phosphoproteomics reveals in vivo insulin signaling dynamics
Sean J. Humphrey et al.
NATURE BIOTECHNOLOGY (2015)
Cell type- and brain region-resolved mouse brain proteome
Kirti Sharma et al.
NATURE NEUROSCIENCE (2015)
Investigation of the role of βarrestin2 in kappa opioid receptor modulation in a mouse model of pruritus
Jenny Morgenweck et al.
NEUROPHARMACOLOGY (2015)
Ribosomal Protein S6 Phosphorylation in the Nervous System: From Regulation to Function
Anne Biever et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2015)
The G Protein-Biased kappa-Opioid Receptor Agonist RB-64 Is Analgesic with a Unique Spectrum of Activities In Vivo
Kate L. White et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Fulfilling the Promise of Biased G Protein-Coupled Receptor Agonism
Louis M. Luttrell et al.
MOLECULAR PHARMACOLOGY (2015)
Functional selectivity of GPCR signaling in animals
Lei Zhou et al.
CURRENT OPINION IN CELL BIOLOGY (2014)
l-Isocorypalmine reduces behavioral sensitization and rewarding effects of cocaine in mice by acting on dopamine receptors
Wei Xu et al.
DRUG AND ALCOHOL DEPENDENCE (2013)
Construction of human activity-based phosphorylation networks
Robert H. Newman et al.
MOLECULAR SYSTEMS BIOLOGY (2013)
Rapamycin attenuates the expression of cocaine-induced place preference and behavioral sensitization
Jeffrey Bailey et al.
ADDICTION BIOLOGY (2012)
Efficacy and Safety of a Novel K-Agonist for Managing Intractable Pruritus in Dialysis Patients
Hiroo Kumagai et al.
AMERICAN JOURNAL OF NEPHROLOGY (2012)
Dynamics of the G Protein-coupled Vasopressin V2 Receptor Signaling Network Revealed by Quantitative Phosphoproteomics
Jason D. Hoffert et al.
MOLECULAR & CELLULAR PROTEOMICS (2012)
Comparative Proteomic Analysis of Eleven Common Cell Lines Reveals Ubiquitous but Varying Expression of Most Proteins
Tamar Geiger et al.
MOLECULAR & CELLULAR PROTEOMICS (2012)
Selective p38α MAPK Deletion in Serotonergic Neurons Produces Stress Resilience in Models of Depression and Addiction
Michael R. Bruchas et al.
NEURON (2011)
Investigation of gastrin-releasing peptide as a mediator for 5′-guanidinonaltrindole-induced compulsive scratching in mice
Saadet Inan et al.
PEPTIDES (2011)
The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder
Courtney S. Jernigan et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2011)
Kappa Opioid Receptor Function
Julia C. Lemos et al.
OPIATE RECEPTORS, SECOND EDITION (2011)
Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study
Hiroo Kumagai et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2010)
Global phosphorylation analysis of β-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR)
Kunhong Xiao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Nanxin Li et al.
SCIENCE (2010)
Specification of Neuronal Polarity Regulated by Local Translation of CRMP2 and Tau via the mTOR-p70S6K Pathway
Tsuyoshi Morita et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Effects of Atypical kappa-Opioid Receptor Agonists on Intrathecal Morphine-Induced Itch and Analgesia in Primates
Mei-Chuan Ko et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
NALFURAFINE HYDROCHLORIDE: A NEW DRUG FOR THE TREATMENT OF UREMIC PRURITUS IN HEMODIALYSIS PATIENTS
Kaoru Nakao et al.
DRUGS OF TODAY (2009)
Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: Effects on mTORC1 and Akt signaling lead to improved survival and function
Lynsey Meikle et al.
JOURNAL OF NEUROSCIENCE (2008)
MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification
Juergen Cox et al.
NATURE BIOTECHNOLOGY (2008)
Systemic inhibition of mammalian target of rapamycin inhibits fear memory reconsolidation
Jacqueline Blundell et al.
NEUROBIOLOGY OF LEARNING AND MEMORY (2008)
2-methoxymethyl-salvinorin B is a potent κ opioid receptor agonist with longer lasting action in vivo than salvinorin A
Yulin Wang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Stress-induced p38 mitogen-activated protein kinase activation mediates κ-opioid-dependent dysphoria
Michael R. Bruchas et al.
JOURNAL OF NEUROSCIENCE (2007)
A curated compendium of phosphorylation motifs
Ramars Amanchy et al.
NATURE BIOTECHNOLOGY (2007)
Antinociceptive and hypothermic effects of salvinorin A are abolished in a novel strain of κ-opioid receptor-1 knockout mice
Michael A. Ansonoff et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Kappa opioid receptor activation of p38 MAPK is GRK3-and arrestin-dependent in neurons and astrocytes
Michael R. Bruchas et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Comparison of pharmacological activities of three distinct kappa ligands (salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo
Y Wang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Effects of κ-opioid receptor ligands on intracranial self-stimulation in rats
MS Todtenkopf et al.
PSYCHOPHARMACOLOGY (2004)
Involvement of central μ-opioid system in the scratching behavior in mice, and the suppression of it by the activation of κ-opioid system
H Umeuchi et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2003)
Salvinorin A:: A potent naturally occurring nonnitrogenous κ opioid selective agonist
BL Roth et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD
H Harada et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
The novel κ-opioid receptor agonist TRK-820 suppresses the rewarding and locomotor-enhancing effects of morphine in mice
M Tsuji et al.
LIFE SCIENCES (2001)
Characterization of the antinociceptive effects of TRK-820 in the rat
T Endoh et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2000)
Share Paper
